2021年11月3日至12月19日美国5-11岁儿童COVID-19疫苗安全性
CDC分析了2021年11月3日至12月19日5-11岁儿童接种辉瑞-BioNTech COVID-19疫苗后VAERS和v-safe报告的不良事件。v-safe中约42504名儿童入组,第2剂后17,180名(57.5%)报告局部反应,12,223名(40.9%)报告全身反应。初步安全性发现与授权前临床试验相似,ACIP推荐该疫苗用于5-11岁儿童预防COVID-19。
要点
- v-safe中第2剂后局部和全身反应报告率分别为57.5%和40.9%,常见为注射部位疼痛、疲劳或头痛。
- ACIP推荐辉瑞-BioNTech COVID-19疫苗用于5-11岁儿童预防COVID-19。
核心结论
- 初步安全性发现与授权前临床试验相似。
- CDC和FDA将继续监测疫苗安全性,并视需要提供更新以指导COVID-19疫苗接种建议。
研究设计与样本
- CDC审查了2021年11月3日至12月19日期间5-11岁儿童接种辉瑞-BioNTech COVID-19疫苗后向VAERS(被动疫苗安全监测系统)报告的不良事件,以及向v-safe(基于智能手机的自愿安全监测系统)报告的不良事件和健康影响评估。
主要发现
- VAERS收到4249份该年龄组接种后不良事件报告,其中4149份(97.6%)为非严重。
- 约42,504名5-11岁儿童在接种后入组v-safe;第2剂后,共报告17,180名(57.5%)局部反应和12,223名(40.9%)全身反应(包括注射部位疼痛、疲劳或头痛)。
关键数值与推荐
- ACIP推荐辉瑞-BioNTech COVID-19疫苗用于5-11岁儿童预防COVID-19。
- FDA修订紧急使用授权,将辉瑞-BioNTech COVID-19(BNT162b2)mRNA疫苗扩大至5-11岁儿童,接种2剂(每剂10 μg,0.2mL),间隔3周。
- 截至2021年12月19日,仅辉瑞-BioNTech COVID-19疫苗被授权用于5-17岁儿童。
临床怎么用
- 应告知5-11岁接种辉瑞-BioNTech COVID-19疫苗儿童的父母和监护人,接种后预期会出现局部和全身反应。
- 接种疫苗是预防COVID-19最有效的方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On October 29, 2021, the Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 (BNT162b2) mRNA vaccine to expand its use to children aged 5-11 years, administered as 2 doses (10 μg, 0.2mL each) 3 weeks apart (1). As of December 19, 2021, only the Pfizer-BioNTech COVID-19 vaccine is authorized for administration to children aged 5-17 years (2,3). In preauthorization clinical trials, Pfizer-BioNTech COVID-19 vaccine was administered to 3,109 children aged 5-11 years; most adverse events were mild to moderate, and no serious adverse events related to vaccination were reported (4). To further characterize safety of the vaccine in children aged 5-11 years, CDC reviewed adverse events after receipt of Pfizer-BioNTech COVID-19 vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), a passive vaccine safety surveillance system co-managed by CDC and FDA, and adverse events and health impact assessments reported to v-safe, a voluntary smartphone-based safety surveillance system for adverse events after COVID-19 vaccination,* during November 3-December 19, 2021. Approximately 8.7 million doses of Pfizer-BioNTech COVID-19 vaccine were administered to children aged 5-11 years† during this period; VAERS received 4,249 reports of adverse events after vaccination with Pfizer-BioNTech COVID-19 vaccine in this age group, 4,149 (97.6%) of which were not serious. Approximately 42,504 children aged 5-11 years were enrolled in v-safe after vaccination with Pfizer-BioNTech COVID-19 vaccine; after dose 2, a total of 17,180 (57.5%) local and 12,223 systemic (40.9%) reactions (including injection-site pain, fatigue, or headache) were reported. The preliminary safety findings are similar to those from preauthorization clinical trials (4,5). The Advisory Committee on Immunization Practices (ACIP) recommends the Pfizer-BioNTech COVID-19 vaccine for children aged 5-11 years for the prevention of COVID-19 (6). Parents and guardians of children aged 5-11 years vaccinated with Pfizer-BioNTech COVID-19 vaccine should be advised that local and systemic reactions are expected after vaccination. Vaccination is the most effective way to prevent COVID-19. CDC and FDA will continue to monitor vaccine safety and will provide updates as needed to guide COVID-19 vaccination recommendations.
引用
- Hause AM, Baggs J, Marquez P, et al. COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34968370. doi:10.15585/mmwr.mm705152a1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。